Future Directions and Unmet Needs in Relapsed/Refractory MCL
A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
Source: onclive.com
Stay updated with breaking news from Shine Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.